AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Quchang Ouyang'
:
Abstract PS11-26: A phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-ps11-26
Abstract:
Add to Library
Authors:
C. Kent Osborne
Donald Richards
Sharon Wilks
Sami Diab
Dejan Juric
Kate Lathrop
Andrea Silber
William J. Edenfield
Amardeep Aulakh
Ben Cho
Binghe Xu
Tao Sun
Quchang Ouyang
Yanxia Shi
Kathryn Stazzone
Zhe Shi
Ling Zhang
Yaolin Wang
Erika Hamilton
Abstract 1660: Preliminary safety tolerability & efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with Nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC)
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.am2021-1660
Abstract:
Add to Library
Authors:
Binghe Xu
Qiao Li
Qingyuan Zhang
Yue Zhang
Quchang Ouyang
Yang Zhang
Qiang Liu
Tao Sun
June Xu
Jing Yang
Yue Yang
Xin Luo
Paul Kong
Ting Xu
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance
Publication Year: 2018
DOI: https://doi.org/10.1016/j.ebiom.2018.05.015
Abstract:
Add to Library
Authors:
Zhe-Yu Hu
Ning Xie
Can Tian
Xiaohong Yang
Liping Liu
Jing Li
Huawu Xiao
Hui Wu
Jun Lü
Jianxiang Gao
Xuming Hu
Min Cao
Zhengrong Shui
Mengjia Xiao
Yu Tang
Qiongzhi He
Lianpeng Chang
Xuefeng Xia
Xin Yi
Qianjin Liao
Quchang Ouyang
Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-gs3-02
Abstract:
Add to Library
Authors:
Binghe Xu
Min Yan
Fei Ma
Xichun Hu
Jifeng Feng
Quchang Ouyang
Zhongsheng Tong
Huiping Li
Qingyuan Zhang
Tao Sun
Xian Wang
Yongmei Yin
Ying Cheng
Wěi Li
Xiaoyu Zhu
Chunxia Chen
Jianjun Zou
Abstract GS1-06: A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-gs1-06
Abstract:
Add to Library
Authors:
Binghe Xu
Qingyuan Zhang
Xichun Hu
Qing Li
Tao Sun
Wěi Li
Quchang Ouyang
Jingfen Wang
Zhongsheng Tong
Min Yan
Huiping Li
Fan Zhang
Changping Shan
Xian Wang
Xi Yan
Jian Zhang
Yue Zhang
Jiani Wang
Liang Zhang
Ying Lin
Jifeng Feng
Qianjun Chen
Jian Huang
Yongkui Lu
Hongsheng Li
Jinsheng Wu
Jing Cheng
Yanrong Hao
Cuizhi Geng
Min Lu
Yanping Li
Xi Chen
Lihua Song
Xueying Wu
Changlu Hu
Xinhong Wu
Xiaojia Wang
Yueyin Pan
Yuehong Cui
Guohua Yu
Sanyuan Sun
Abstract OT1-03-02: Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-ot1-03-02
Abstract:
Add to Library
Authors:
Yongmei Yin
Xinhong Wu
Quchang Ouyang
Min Yan
Lihua Song
Yunpeng Liu
Zhongsheng Tong
Cuizhi Geng
Ying Wang
Guohua Yu
Xiang Wang
Ying Cheng
Weihong Zhao
Qun Li
Yina Diao
Gesha Liu
Junyou Ge
Jin Li
Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study
Publication Year: 2020
DOI: https://doi.org/10.21037/tbcr-20-25
Abstract:
Add to Library
Authors:
Min Yan
Li Bian
Xichun Hu
Qingyuan Zhang
Quchang Ouyang
Jifeng Feng
Yongmei Yin
Tao Sun
Zhongsheng Tong
Xiaojia Wang
Herui Yao
Jianjun Zou
Xiaoyu Zhu
Zefei Jiang
Abstract P2-13-40: Treatment patterns and adverse events of pyrotinib-based therapy in HER2-positive breast cancer patients in China: Results from a multicenter, real-world study
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-p2-13-40
Abstract:
Add to Library
Authors:
Yiqun Li
Zhongsheng Tong
Quchang Ouyang
Xinhong Wu
Wei Li
Li Cai
Zhiyong Yu
Zhengxiang Han
Xiaojia Wang
Wei Wang
Jin Yang
Li Li
Zhaofeng Niu
Haibo Wang
Qitang Wang
Yi Li
Yuee Teng
Shi-Guang Zhu
Binghe Xu
Abstract PD18-08: Efficacy and safety results of KN026, a HER2-targeted bispecific antibody combined with docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-pd18-08
Abstract:
Add to Library
Authors:
Qingyuan Zhang
Jingxuan Wang
Quchang Ouyang
Xiaojia Wang
Jingfen Wang
Lu Gan
Daren Lin
Zhong Ouyang
Ting Xu
Yilan Liu
Summer Xia
Abstract PD11-10: PD11-10 Efficacy, Safety, and Tolerability of KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in combination with Nab-paclitaxel in Metastatic Triple-negative Breast Cancer (mTNBC):Final results of the Phase II trial
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-pd11-10
Abstract:
Add to Library
Authors:
Qiao Li
Qingyuan Zhang
Yue Zhang
Quchang Ouyang
Qiang Liu
Tao Sun
Feng Ye
Baochun Zhang
Ting Xu
Summer Xia
Karl Zhang
Bangyong Zhang
Binghe Xu
Abstract PD8-05: Overall survival (OS) results from the phase III PHENIX trial of HER2+ metastatic breast cancer treated with pyrotinib plus capecitabine
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-pd8-05
Abstract:
Add to Library
Authors:
Zefei Jiang
Min Yan
Bian Li
Li Wang
Xichun Hu
Qingyuan Zhang
Quchang Ouyang
Jifeng Feng
Yongmei Yin
Tao Sun
Zhongsheng Tong
Xiaojia Wang
Herui Yao
Shuping Jiang
Xiaoyu Zhu
Jianjun Zou
Abstract PD7-08: Everolimus in first-line treatment of advanced premenopausal breast cancer: Results from MIRACLE (everoliMus trIal foR AdvanCed premenopausaL brEast cancer) study
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-pd7-08
Abstract:
Add to Library
Authors:
Ying Fan
Tao Sun
Zhimin Shao
Qingyuan Zhang
Quchang Ouyang
Zhongsheng Tong
Shusen Wang
Yang Luo
Yuee Teng
Xiaojia Wang
Shu Wang
Qiang Liu
Jifeng Feng
Kunwei Shen
Yanqiu Song
Jiayu Wang
Fei Ma
Qing Li
Pin Zhang
Binghe Xu
Abstract PS13-25: Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-ps13-25
Abstract:
Add to Library
Authors:
Zefei Jiang
Xichun Hu
Qingyuan Zhang
Tao Sun
Yongmei Yin
Huiping Li
Min Yan
Zhongsheng Tong
Christina Oppermann
Yunpeng Liu
Rômulo Leopoldo de Paula Costa
Man Li
Xi Chen
Ying Cheng
Quchang Ouyang
Ning Liao
Xiaojia Wang
Xinhong Wu
Jifeng Feng
Roberto Hegg
Govindbabu Kanaka Setty
Amit Agarwal
Jyoti Bajpai
Jing Cheng
Gustavo Girotto
Chanchal Goswami
Wenjing Hu
Jian Huang
MA Coccia Portugal
Jin Yang
Zheng Rong-sheng
Fábio Franke
Qiang Liu
Yunjiang Liu
Yongkui Lu
Cristiano de Pádua Souza
Shiying Yu
Nalini Kilara
Harsha Panchal
Ashish Singh
Shona Nag
Jian Liu
Bernardo L. Rapoport
Neonyana Keorapetse Rebecca Tabane
Hongxia Wang
Ning Wang
Rubing Han
Wanli Zhang
Establishment of Risk Prediction Model for Brain Metastasis with Breast Cancer by Using ctDNA Genetic Profile and Clinical Features from Real-World Data
Publication Year: 2019
DOI: https://doi.org/10.2139/ssrn.3403366
Abstract:
Add to Library
Authors:
Yu Tang
Liping Lu
Can Tian
Ning Xie
Jingyu Liu
Dabo Zhou
Hui Wang
Yikai Wang
Qiongzhi He
Zhe-Yu Hu
Quchang Ouyang
Abstract PO1-13-01: Safety profiles of Chinese breast cancer patients who received abemaciclib in MONARCH plus and monarchE study
Publication Year: 2024
DOI: https://doi.org/10.1158/1538-7445.sabcs23-po1-13-01
Abstract:
Add to Library
Authors:
Zhimin Shao
Qingyuan Zhang
Quchang Ouyang
Qiang Liu
Jifeng Feng
Huiping Li
Xiaojia Wang
Ning Liao
Yang Liu
Qinyi Zhu
Chenxi Qian
Zefei Jiang
Found 27 results in 0.072 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"